Any extracts used in the following article are for non commercial research and educational purposes only and may be subject to copyright from their respective owners.
A recurrent theme, and one that appears to have (fatally?) tripped up a major drug company and its compliant regulator, is the lack of adequate controls & consistency due to too many variables, especially with constantly evolving viral variants and prior infections.
Thanks Brian. I would value your input.
A recurrent theme, and one that appears to have (fatally?) tripped up a major drug company and its compliant regulator, is the lack of adequate controls & consistency due to too many variables, especially with constantly evolving viral variants and prior infections.